6-thioguanine selectively kills BRCA2 defective tumours and overcomes PARP inhibitor resistance

Familial breast and ovarian cancers are often defective in homologous recombination (HR) due to mutations in the BRCA1 or BRCA2 genes. Cisplatin chemotherapy or poly(ADP-ribose) polymerase (PARP) inhibitors are tested for these tumours in clinical trials. In a screen for novel drugs that selectively...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Issaeva, Natalia, Thomas, Huw D., Djurenovic, Tatjana, Jaspers, Janneke E., Stoimenov, Ivaylo, Kyle, Suzanne, Pedley, Nicholas, Gottipati, Ponnari, Zur, Rafal, Sleeth, Kate, Chatzakos, Vicky, Mulligan, Evan, Lundin, Cecilia, Gubanova, Evgenia, Kersbergen, Ariena, Harris, Adrian L, Sharma, Ricky A, Rottenberg, Sven, Curtin, Nicola J., Helleday, Thomas
Médium: Artigo
Jazyk:Inglês
Vydáno: 2010
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2913123/
https://ncbi.nlm.nih.gov/pubmed/20631063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-09-3416
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky